XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.1
7 Loss Per Common Share
 9 Months Ended
Mar. 31, 2022
7 Loss Per Common Share  
Loss Per Common Share

7. Loss Per Common Share

 

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income, if any, by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive; accordingly, no dilution is shown for loss periods. The following table sets forth the weighted average number of common shares outstanding for each period presented.

 

 

 

For the Three Month Period Ended March 31, 2022

 

 

For the Three Month Period Ended March 31, 2021

 

 

For the Nine Month Period Ended March 31, 2022

 

 

 For the Nine Month Period Ended March 31, 2021

 

Weighted average number of common shares outstanding

 

 

6,633,901

 

 

 

2,861,607

 

 

 

6,544,112

 

 

 

2,861,376

 

Effect of dilutive securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Weighted average number of dilutive common shares outstanding

 

 

6,633,901

 

 

 

2,861,607

 

 

 

6,544,112

 

 

 

2,861,376

 

Basic and diluted loss per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$(0.23)

 

$(0.51)

 

$(0.56)

 

$(0.61)

Discontinued operations

 

$-

 

 

$0.01

 

 

$-

 

 

$(0.20)

Consolidated operations

 

$(0.23)

 

$(0.50)

 

$(0.56)

 

$(0.81)

 

Approximately 3,452,542 and 3,451,461 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2022.

 

Approximately 259,357 and 1,349,850 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2021.